Company profile NKTX
There is not enough data for clinical-stage biopharmaceutical company to provide analysis
There is not enough data for clinical-stage biopharmaceutical company to provide correlation calculation
There is not enough data for clinical-stage biopharmaceutical company to provide analysis
There is not enough data for cell therapies for cancer treatment to provide analysis
There is not enough data for cell therapies for cancer treatment to provide correlation calculation
There is not enough data for cell therapies for cancer treatment to provide analysis
After 39 days of this quarter the interest is at 19.0. Based on that we can calculate that during remaining 52 days it will total up to 44.0. chimeric antigen receptors expected interest is significantly lower compared to same quarter last year (-63.6%) but similar to previous quarter.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 118 | 113 -4.2% QoQ | 140 23.9% QoQ | 43 -69.3% QoQ |
| 2020 | 136 15.3% YoY 216.3% QoQ | 101 -10.6% YoY -25.7% QoQ | 113 -19.3% YoY 11.9% QoQ | 0 -100.0% YoY -100.0% QoQ |
| 2021 | 110 -19.1% YoY inf% QoQ | 22 -78.2% YoY -80.0% QoQ | 91 -19.5% YoY 313.6% QoQ | 193 inf% YoY 112.1% QoQ |
| 2022 | 101 -8.2% YoY -47.7% QoQ | 40 81.8% YoY -60.4% QoQ | 133 46.2% YoY 232.5% QoQ | 111 -42.5% YoY -16.5% QoQ |
| 2023 | 121 19.8% YoY 9.0% QoQ | 58 45.0% YoY -52.1% QoQ | 116 -12.8% YoY 100.0% QoQ | 52 -53.2% YoY -55.2% QoQ |
| 2024 | 19 -84.3% YoY -63.5% QoQ | - | - | - |
The average 5 years interest of chimeric antigen receptors was 7.4 per week. The last year interest of chimeric antigen receptors compared to the last 5 years has changed by -25.41%. This is something to be checked. The last year interest is quite lower compared to 5 years ago. It has decreased by -38.94%.
After 39 days of this quarter the interest is at 423.0. Based on that we can calculate that during remaining 52 days it will total up to 987.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 484 | 667 37.8% QoQ | 665 -0.3% QoQ | 676 1.7% QoQ |
| 2020 | 773 59.7% YoY 14.3% QoQ | 686 2.8% YoY -11.3% QoQ | 750 12.8% YoY 9.3% QoQ | 727 7.5% YoY -3.1% QoQ |
| 2021 | 839 8.5% YoY 15.4% QoQ | 781 13.8% YoY -6.9% QoQ | 756 0.8% YoY -3.2% QoQ | 778 7.0% YoY 2.9% QoQ |
| 2022 | 1060 26.3% YoY 36.2% QoQ | 931 19.2% YoY -12.2% QoQ | 828 9.5% YoY -11.1% QoQ | 900 15.7% YoY 8.7% QoQ |
| 2023 | 1040 -1.9% YoY 15.6% QoQ | 945 1.5% YoY -9.1% QoQ | 902 8.9% YoY -4.6% QoQ | 1025 13.9% YoY 13.6% QoQ |
| 2024 | 423 -59.3% YoY -58.7% QoQ | - | - | - |
The average 5 years interest of lymphocyte was 63.74 per week. The last year interest of lymphocyte compared to the last 5 years has changed by 17.6%. The interest for lymphocyte is relatively stable and increasing in the last 5 years. The last year interest is quite higher compared to 5 years ago. It has increased by 40.06%.
There is not enough data for specific proteins or antigens to provide analysis
There is not enough data for specific proteins or antigens to provide correlation calculation
There is not enough data for specific proteins or antigens to provide analysis
After 39 days of this quarter the interest is at 397.0. Based on that we can calculate that during remaining 52 days it will total up to 926.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 425 | 495 16.5% QoQ | 436 -11.9% QoQ | 551 26.4% QoQ |
| 2020 | 633 48.9% YoY 14.9% QoQ | 538 8.7% YoY -15.0% QoQ | 495 13.5% YoY -8.0% QoQ | 684 24.1% YoY 38.2% QoQ |
| 2021 | 586 -7.4% YoY -14.3% QoQ | 554 3.0% YoY -5.5% QoQ | 450 -9.1% YoY -18.8% QoQ | 624 -8.8% YoY 38.7% QoQ |
| 2022 | 828 41.3% YoY 32.7% QoQ | 742 33.9% YoY -10.4% QoQ | 574 27.6% YoY -22.6% QoQ | 892 42.9% YoY 55.4% QoQ |
| 2023 | 915 10.5% YoY 2.6% QoQ | 803 8.2% YoY -12.2% QoQ | 657 14.5% YoY -18.2% QoQ | 1013 13.6% YoY 54.2% QoQ |
| 2024 | 397 -56.6% YoY -60.8% QoQ | - | - | - |
The average 5 years interest of tumor cells was 50.93 per week. The last year interest of tumor cells compared to the last 5 years has changed by 28.23%. The interest for tumor cells is trending. The last year interest is quite higher compared to 5 years ago. It has increased by 58.79%.
After 39 days of this quarter the interest is at 46.0. Based on that we can calculate that during remaining 52 days it will total up to 107.0. NKX101 expected interest is significantly higher compared to same quarter last year (+613.3%) but similar to previous quarter.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 26 | 43 65.4% QoQ | 0 -100.0% QoQ | 92 inf% QoQ |
| 2020 | 50 92.3% YoY -45.7% QoQ | 77 79.1% YoY 54.0% QoQ | 92 inf% YoY 19.5% QoQ | 107 16.3% YoY 16.3% QoQ |
| 2021 | 47 -6.0% YoY -56.1% QoQ | 32 -58.4% YoY -31.9% QoQ | 83 -9.8% YoY 159.4% QoQ | 163 52.3% YoY 96.4% QoQ |
| 2022 | 88 87.2% YoY -46.0% QoQ | 30 -6.2% YoY -65.9% QoQ | 64 -22.9% YoY 113.3% QoQ | 77 -52.8% YoY 20.3% QoQ |
| 2023 | 15 -83.0% YoY -80.5% QoQ | 68 126.7% YoY 353.3% QoQ | 106 65.6% YoY 55.9% QoQ | 115 49.4% YoY 8.5% QoQ |
| 2024 | 46 206.7% YoY -60.0% QoQ | - | - | - |
The average 5 years interest of NKX101 was 5.44 per week. The last year interest of NKX101 compared to the last 5 years has changed by 18.38%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 107.74%.
After 39 days of this quarter the interest is at 16.0. Based on that we can calculate that during remaining 52 days it will total up to 37.0. Phase I clinical trials expected interest is significantly lower compared to previous quarter (-79.2%) and same quarter last year (-84.1%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 81 | 144 77.8% QoQ | 126 -12.5% QoQ | 101 -19.8% QoQ |
| 2020 | 257 217.3% YoY 154.5% QoQ | 145 0.7% YoY -43.6% QoQ | 207 64.3% YoY 42.8% QoQ | 219 116.8% YoY 5.8% QoQ |
| 2021 | 188 -26.8% YoY -14.2% QoQ | 241 66.2% YoY 28.2% QoQ | 145 -30.0% YoY -39.8% QoQ | 115 -47.5% YoY -20.7% QoQ |
| 2022 | 187 -0.5% YoY 62.6% QoQ | 234 -2.9% YoY 25.1% QoQ | 168 15.9% YoY -28.2% QoQ | 141 22.6% YoY -16.1% QoQ |
| 2023 | 232 24.1% YoY 64.5% QoQ | 225 -3.8% YoY -3.0% QoQ | 133 -20.8% YoY -40.9% QoQ | 178 26.2% YoY 33.8% QoQ |
| 2024 | 16 -93.1% YoY -91.0% QoQ | - | - | - |
The average 5 years interest of Phase I clinical trials was 13.34 per week. The last year interest of Phase I clinical trials compared to the last 5 years has changed by 3.67%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 36.26%.
There is not enough data for relapsed/refractory acute myeloid leukemia to provide analysis
There is not enough data for relapsed/refractory acute myeloid leukemia to provide correlation calculation
There is not enough data for relapsed/refractory acute myeloid leukemia to provide analysis
There is not enough data for higher risk myelodysplastic syndromes to provide analysis
There is not enough data for higher risk myelodysplastic syndromes to provide correlation calculation
There is not enough data for higher risk myelodysplastic syndromes to provide analysis
Google Trends for NKX019
Q4 +349.2% YoY, +275.3% QoQ | Q1 +914.3% YoY, -22.3% QoQ | Correlation: nan
After 39 days of this quarter the interest is at 150.0. Based on that we can calculate that during remaining 52 days it will total up to 350.0. NKX019 expected interest is significantly higher compared to previous quarter (+386.1%) and same quarter last year (+493.2%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 0 | 108 inf% QoQ | 67 -38.0% QoQ | 32 -52.2% QoQ |
| 2020 | 68 inf% YoY 112.5% QoQ | 78 -27.8% YoY 14.7% QoQ | 86 28.4% YoY 10.3% QoQ | 68 112.5% YoY -20.9% QoQ |
| 2021 | 78 14.7% YoY 14.7% QoQ | 24 -69.2% YoY -69.2% QoQ | 91 5.8% YoY 279.2% QoQ | 179 163.2% YoY 96.7% QoQ |
| 2022 | 90 15.4% YoY -49.7% QoQ | 46 91.7% YoY -48.9% QoQ | 28 -69.2% YoY -39.1% QoQ | 0 -100.0% YoY -100.0% QoQ |
| 2023 | 59 -34.4% YoY inf% QoQ | 57 23.9% YoY -3.4% QoQ | 0 -100.0% YoY -100.0% QoQ | 72 inf% YoY inf% QoQ |
| 2024 | 150 154.2% YoY 108.3% QoQ | - | - | - |
The average 5 years interest of NKX019 was 5.29 per week. The last year interest of NKX019 compared to the last 5 years has changed by 14.56%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 52.26%.
There is not enough data for various B cell malignancies to provide analysis
There is not enough data for various B cell malignancies to provide correlation calculation
There is not enough data for various B cell malignancies to provide analysis
After 39 days of this quarter the interest is at 74.0. Based on that we can calculate that during remaining 52 days it will total up to 173.0. CD19 antigen expected interest is significantly lower compared to previous quarter (-41.6%) but similar to same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 31 | 58 87.1% QoQ | 170 193.1% QoQ | 65 -61.8% QoQ |
| 2020 | 174 461.3% YoY 167.7% QoQ | 56 -3.4% YoY -67.8% QoQ | 119 -30.0% YoY 112.5% QoQ | 25 -61.5% YoY -79.0% QoQ |
| 2021 | 89 -48.9% YoY 256.0% QoQ | 100 78.6% YoY 12.4% QoQ | 196 64.7% YoY 96.0% QoQ | 27 8.0% YoY -86.2% QoQ |
| 2022 | 390 338.2% YoY 1344.4% QoQ | 178 78.0% YoY -54.4% QoQ | 139 -29.1% YoY -21.9% QoQ | 154 470.4% YoY 10.8% QoQ |
| 2023 | 133 -65.9% YoY -13.6% QoQ | 111 -37.6% YoY -16.5% QoQ | 95 -31.7% YoY -14.4% QoQ | 296 92.2% YoY 211.6% QoQ |
| 2024 | 74 -44.4% YoY -75.0% QoQ | - | - | - |
The average 5 years interest of CD19 antigen was 10.27 per week. The last year interest of CD19 antigen compared to the last 5 years has changed by 19.86%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 64.13%.
There is not enough data for research collaboration agreement with CRISPR Therapeutics AG to provide analysis
There is not enough data for research collaboration agreement with CRISPR Therapeutics AG to provide correlation calculation
There is not enough data for research collaboration agreement with CRISPR Therapeutics AG to provide analysis